title: Use of the statins in patients after acute myocardial infarction: does evidence change practice?
abstract: OBJECTIVE
  To compare the use of lipid-lowering agents in 42 628 elderly patients (aged > or =65 years) after acute myocardial infarction, before and after the publication of the Scandinavian Simvastatin Survival Study (4S), using the Ontario Myocardial Infarction Database.
  
  
  METHODS
  Multivariate regression models were created to estimate changes in the rate of statin use over time in monthly cohorts of elderly patients after acute myocardial infarction in Ontario from April 1, 1992, to March 31, 1997. Changes in the rate of statin use over time were estimated using patient and prescriber characteristics.
  
  
  RESULTS
  We found a 3.6-fold significant increase in the monthly rate of statin use after the publication of 4S compared with before the publication of 4S (P<.001); specifically, the rate of increase in simvastatin and pravastatin sodium use was higher after the publication of 4S (P<.001 for each). Before the publication of 4S, the rate of increase in statin use in younger patients (aged 65-74 years) was 2.7 times higher than in older patients (aged > or =75 years) (P =.02), while after the publication of 4S, the rate of increase in statin use was only 1.8-fold higher in the younger group (P<.001). After the publication of 4S, there was a 1.6-fold higher rate of increase in statin use in male compared with female patients (P =.006). Also after the publication of 4S, specialists (cardiologists and internists) had a 2-fold higher rate of increased use of the statins than did generalists (P<.001).
  
  
  CONCLUSIONS
  It is possible to shift practice if the evidence of benefit is strong, the intervention is easy to implement, and the intervention is marketed aggressively.
authors.affiliation: Pharmacy Department, University Health Network-Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4. cynthia.jackevicius@uhn.on.ca
authors.forename: C A
authors.initials: CA
authors.lastname: Jackevicius
authors.forename: G M
authors.initials: GM
authors.lastname: Anderson
authors.forename: L
authors.initials: L
authors.lastname: Leiter
authors.forename: J V
authors.initials: JV
authors.lastname: Tu
mesh_terms: D000368:Aged; D002986:Clinical Trials as Topic; D004363:Drug Utilization; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008511:Medicine; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D010818:Practice Patterns, Physicians'; D017035:Pravastatin / Q000627:therapeutic use*; D011643:Publishing; D019821:Simvastatin / Q000627:therapeutic use*; D013038:Specialization; D015996:Survival Rate
chemical_list: D000960:Hypolipidemic Agents; D008055:Lipids; D019821:Simvastatin; D017035:Pravastatin